Marker Systems Based on MicroRNA Gene Methylation for the Diagnosis of Stage I-II Breast Cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Groups of microRNA genes, methylation of which is associated with the initial (I-II) stages of breast cancer, are determined, and new markers and marker systems for the disease diagnosis were created on the basis of these data. A total of 14 genes in which methylation was associated with breast cancer were identified with the use of methyl-specific PCR on a representative sample of 70 tumor specimens. Analysis of 46 specimens from patients with clinical stages I and II detected 9 genes (MIR-124-1, MIR-124-3, MIR-125b-1, MIR-129-2, MIR-132, MIR-148a, MIR-193a, MIR-34b/c, and MIR-9-3), in which methylation was associated with the initial stages of the disease. Using ROC analysis, we formed two systems including 6 markers each and detecting breast cancer at stages I-II with high sensitivity (89 and 91%) and specificity (88%) at AUC=0.92-0.93. These sets were validated on the total sample of 70 specimens including all disease stages; they showed 93 and 94% sensitivities, 88% specificity, and AUC=0.95. Highly sensitive systems of markers, based on microRNA gene methylation, were created for the diagnosis of breast cancer at stages I-II.

作者简介

E. Braga

Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center

编辑信件的主要联系方式.
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

M. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

D. Khodyrev

Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Biomedical Agency of Russia

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow

N. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019
##common.cookie##